INTRODUCTION AND HYPOTHESIS: The aims of this study are (1) to assess the reliability (test-retest) of the Urgency Severity and Life Impact Questionnaire (USIQ) and (2) to test the effect of extended-release tolterodine on symptoms of urinary urgency using this validated instrument. METHODS: To measure reliability, women with overactive bladder (OAB) completed the USIQ on two separate occasions, prior to treatment for OAB. To assess the responsiveness, the USIQ participants completed the above-mentioned questionnaires prior to and following 4 weeks of treatment for OAB with extended-release tolterodine. RESULTS: USIQ-S and USIQ-QoL scores at the two visits did not differ significantly. Repeated measures of USIQ-S and USIQ-QoL demonstrated a moderate to excellent intraclass correlation coefficient (0.64-0.74; P < 0.0001 and 0.48-0.91, P < 0.0001, respectively). A significant decrease in mean USIQ-S and USIQ-QOL (71 ± 14 vs. 44 ± 19, P < 0.0001 and 51 ± 22 vs. 39 ± 10, P < 0.01, respectively) scores following treatment with tolterodine. CONCLUSIONS: This valid, reliable measure can be used in clinical practice and research trials to measure urgency severity.
INTRODUCTION AND HYPOTHESIS: The aims of this study are (1) to assess the reliability (test-retest) of the Urgency Severity and Life Impact Questionnaire (USIQ) and (2) to test the effect of extended-release tolterodine on symptoms of urinary urgency using this validated instrument. METHODS: To measure reliability, women with overactive bladder (OAB) completed the USIQ on two separate occasions, prior to treatment for OAB. To assess the responsiveness, the USIQ participants completed the above-mentioned questionnaires prior to and following 4 weeks of treatment for OAB with extended-release tolterodine. RESULTS:USIQ-S and USIQ-QoL scores at the two visits did not differ significantly. Repeated measures of USIQ-S and USIQ-QoL demonstrated a moderate to excellent intraclass correlation coefficient (0.64-0.74; P < 0.0001 and 0.48-0.91, P < 0.0001, respectively). A significant decrease in mean USIQ-S and USIQ-QOL (71 ± 14 vs. 44 ± 19, P < 0.0001 and 51 ± 22 vs. 39 ± 10, P < 0.01, respectively) scores following treatment with tolterodine. CONCLUSIONS: This valid, reliable measure can be used in clinical practice and research trials to measure urgency severity.
Authors: Christopher R Chapple; Walter Artibani; Linda D Cardozo; David Castro-Diaz; Michael Craggs; Francois Haab; Vik Khullar; Eboo Versi Journal: BJU Int Date: 2005-02 Impact factor: 5.588
Authors: M D Vardy; H D Mitcheson; T-A Samuels; J D Wegenke; S Forero-Schwanhaeuser; T S Marshall; W He Journal: Int J Clin Pract Date: 2009-12 Impact factor: 2.503
Authors: Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer Journal: Neurourol Urodyn Date: 2010 Impact factor: 2.696
Authors: Eric S Rovner; Karl Kreder; David O Sussman; Steven A Kaplan; Martin Carlsson; Tamara Bavendam; Zhonghong Guan Journal: J Urol Date: 2008-07-17 Impact factor: 7.450
Authors: Lior Lowenstein; Mary P FitzGerald; Kimberly Kenton; Lena Hatchett; Ramon Durazo-Arvizu; Elizabeth R Mueller; Kara Goldman; Linda Brubaker Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2008-11-20
Authors: Karin S Coyne; Chris C Sexton; Christine Thompson; Tamara Bavendam; Linda Brubaker Journal: Int Urogynecol J Date: 2014-06-19 Impact factor: 2.894